



ATTENTION:

**ATROVENT® (IPRATROPIUM BROMIDE) INHALATION AEROSOL
(CFC FORMULATION) MDI IS BEING DISCONTINUED**

Now is the time to

**Consider stepping up to the
sustained efficacy of SPIRIVA^{1,2}**

A coupon for a free 30-day supply of SPIRIVA is enclosed.

SPIRIVA HandiHaler is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

SPIRIVA HandiHaler is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, ie, ipratropium, or to any component of this product and is not indicated for the initial treatment of acute episodes of bronchospasm, ie, rescue therapy. The most commonly reported adverse drug reaction was dry mouth, which was mild and often resolved during continued treatment.

 **SPIRIVA[®] HandiHaler[®]**
(tiotropium bromide inhalation powder)



Receiving a free one-month supply of SPIRIVA HandiHaler is easy:

- ▶ **Physician:** This savings certificate program allows your patients to receive a free, one-month supply of SPIRIVA HandiHaler. Please affix this sticker to a completed, signed prescription. Attach the bottom portion of the sticker to the patient's chart.
- ▶ **Patient:** Prescription can be taken to any pharmacy for a free one-month supply of SPIRIVA.

 **SPIRIVA® HandiHaler®**
(tiotropium bromide inhalation powder)



Good for one 30-day supply of SPIRIVA (tiotropium bromide inhalation powder). Redeem for product only when affixed to the back of a valid, signed prescription form of SPIRIVA HandiHaler. No substitutions permitted. No purchase required. Submit claim to McKesson Specialty Arizona, Inc. using BIN #610500. For pharmacy processing questions, please call the Help Desk at 1-800-750-9835.

Group # H1527002 ID # Z03708670

Good through 4/30/2006. Void where prohibited by law. Product dispensed pursuant to terms of voucher shall not be submitted to any private third-party payer, such as Medicaid or any similar federal state healthcare program, for reimbursement. Not valid if reproduced or submitted to other payer. It is illegal for any person to sell, purchase, or trade, or offer to sell, purchase, or trade, or to counterfeit, this voucher.

McKesson retains the right to review all records and documentation relating to the filing/dispensing of product.

TrialScript® is a registered trademark of McKesson Corporation.

Prescriber ID # required on prescription.



Components of:



Boehringer
Ingelheim





SPIRIVA: Same copay tier as Atrovent® (ipratropium bromide) Inhalation Aerosol with most major insurers

A first-line maintenance therapy in chronic bronchitis and emphysema

Consider stepping up to the sustained efficacy of SPIRIVA^{1,2}

- ▶ **Superior** predose FEV₁* through 1 year vs ipratropium^{1,2}
- ▶ **Sustained** predose FEV₁ improvements through 1 year vs ipratropium^{1,2}
- ▶ **Established** safety profile

*FEV₁ = forced expiratory volume in 1 second.

SPIRIVA HandiHaler is intended as a once-daily maintenance treatment for COPD and is not indicated for the initial treatment of acute episodes of bronchospasm, ie, rescue therapy.

As an anticholinergic drug, SPIRIVA may potentially worsen symptoms and signs associated with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction and should be used with caution in patients with any of these conditions.

As a predominantly renally excreted drug, SPIRIVA use should be monitored closely in patients with moderate to severe renal impairment (creatinine clearance of ≤ 50 mL/min).

SPIRIVA has been used concomitantly with other drugs commonly used in COPD (these include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids) without increases in adverse drug reactions. However, the coadministration of SPIRIVA with other anticholinergic-containing drugs (eg, ipratropium) has not been studied and is therefore not recommended.

Please see enclosed full Prescribing Information for SPIRIVA HandiHaler.

References: 1. Data on File, Boehringer Ingelheim Pharmaceuticals, Inc. 2. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. *Eur Respir J*. 2002;19:209-216.

